Hua Medicine on Earnings, Business Expansion Plans

Chinese biotech firm Hua Medicine sees robust growth in 2026 after reporting a 93 jump in full-year revenue. Speaking exclusively to Bloomberg's The China Show, Chief Strategy Officer George Lin discusses the outlook for the company’s flagship drug dorzagliatin and plans to expand to additional markets. (Source: Bloomberg)